Compare INTZ & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | HOWL |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4M | 17.9M |
| IPO Year | 2020 | 2021 |
| Metric | INTZ | HOWL |
|---|---|---|
| Price | $0.67 | $0.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.75 | $5.00 |
| AVG Volume (30 Days) | 207.3K | ★ 555.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,015,000.00 | N/A |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.65 | $0.27 |
| 52 Week High | $2.27 | $2.23 |
| Indicator | INTZ | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 52.04 |
| Support Level | N/A | $0.40 |
| Resistance Level | $0.88 | $0.43 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 13.84 | 32.73 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.